Cascade new FXR agonist CS0159 completed the administration of the first subject in clinical phase I

On December 7, 2021, Cascade Pharmaceuticals, Inc announced that the new class I drug CS0159 developed by the company had completed the first administration to the subjects.

Dr. Eric Xu, founder of the company, said:

"With the efficient cooperation of the Cascade team, CS0159 soon reached the milestone of the first subject administration after obtaining the FDA clinical implied license. The Phase I clinical study aims to evaluate the safety, tolerance and pharmacokinetic characteristics of CS0159 in healthy people. The smooth implementation of this study can accelerate the clinical research process of CS0159. At the same time, the IND application of CS0159 in China has also been submitted recently. The follow-up company will We will continue to carry out more research and development of original new drugs, help life achieve health, and make the pain treatable. "